Physician profile
Augusto C Juguilon
NPI 1043269434
$1,105.77
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $231 · 2022: $15.12 · 2023: $66.43 · 2024: $71.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $104 · Education: $33.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $104.41 |
| Education | $33.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $554.81 | 2019-2020 | |
| Abbvie INC. | $119.53 | 2022-2024 | |
| Scilex Pharmaceuticals INC. | $67.81 | 2019 | |
| Biogen, INC. | $53.89 | 2019 | |
| Ucb, INC. | $44.06 | 2019 | |
| Emd Serono, INC. | $40.18 | 2019 | |
| Greenwich Biosciences, INC. | $34.32 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $33.44 | 2024 | |
| Eisai INC. | $20.67 | 2019 | |
| Genzyme Corporation | $19.94 | 2019 | |
| Lilly USA, LLC | $19.00 | 2019 | |
| Amgen INC. | $18.92 | 2019 | |
| Amneal Pharmaceuticals LLC | $16.50 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.71 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $12.15 | 2019 | |
| Strongbridge US INC. | $11.22 | 2019 | |
| Mdd US Operations, LLC | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augusto Juguilon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.